Meeting Report
Melanoma: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Lisa Kottschade, APRN, MSN, CNP
Mayo Clinic
J Adv Pract Oncol 2020;11(6):609-611 |
https://doi.org/10.6004/jadpro.2020.11.6.8 |
© 2020 Harborside™
ABSTRACT
With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews clinical data on which patients with metastatic melanoma should receive combination therapy vs. single-agent PD-1 up front, and what to do at the time of progression on PD-1 monotherapy.
For access to the full length article, please
sign in.
